Busey Trust CO acquired a new stake in Edwards Lifesciences Corp (NYSE:EW) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,564 shares of the medical research company’s stock, valued at approximately $272,000.
A number of other hedge funds and other institutional investors have also modified their holdings of EW. Wendell David Associates Inc. raised its holdings in Edwards Lifesciences by 4.9% during the 3rd quarter. Wendell David Associates Inc. now owns 10,015 shares of the medical research company’s stock worth $1,744,000 after purchasing an additional 467 shares during the last quarter. LFA Lugano Financial Advisors SA bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $121,000. Iberiabank Corp raised its holdings in Edwards Lifesciences by 35.8% during the 3rd quarter. Iberiabank Corp now owns 24,008 shares of the medical research company’s stock worth $4,180,000 after purchasing an additional 6,333 shares during the last quarter. Ipswich Investment Management Co. Inc. bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $854,000. Finally, Capital Insight Partners LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $1,899,000. Institutional investors and hedge funds own 82.10% of the company’s stock.
In related news, VP Huimin Wang sold 3,800 shares of Edwards Lifesciences stock in a transaction on Monday, August 6th. The shares were sold at an average price of $144.99, for a total value of $550,962.00. Following the completion of the sale, the vice president now owns 88,483 shares of the company’s stock, valued at approximately $12,829,150.17. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Larry L. Wood sold 6,300 shares of Edwards Lifesciences stock in a transaction on Monday, July 16th. The shares were sold at an average price of $148.02, for a total transaction of $932,526.00. Following the completion of the sale, the vice president now directly owns 121,950 shares of the company’s stock, valued at approximately $18,051,039. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 158,811 shares of company stock valued at $22,738,863. Insiders own 1.84% of the company’s stock.
Shares of EW stock opened at $143.39 on Friday. The company has a market cap of $36.45 billion, a PE ratio of 37.50, a P/E/G ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 52 week low of $100.20 and a 52 week high of $175.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $972.00 million during the quarter, compared to the consensus estimate of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.08 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corp will post 4.67 earnings per share for the current fiscal year.
Several research analysts have issued reports on EW shares. Sanford C. Bernstein started coverage on shares of Edwards Lifesciences in a report on Wednesday, June 27th. They set a “market perform” rating and a $165.00 price target for the company. BMO Capital Markets raised their price target on shares of Edwards Lifesciences to $162.00 and gave the stock an “outperform” rating in a report on Tuesday, July 10th. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Saturday, July 14th. Northland Securities restated a “hold” rating and set a $120.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a $168.00 price target on shares of Edwards Lifesciences in a report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $155.30.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.